Pamela B. Sylvestre

Pamela B. Sylvestre

Auto-generated profile, based on publicly available information

Pamela B. Sylvestre

Department of Pathology Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
NTNoble Kumar Talari
Noble Kumar Talari
UMUshodaya Mattam
Ushodaya Mattam
ARAfra P. Rahman
Afra P. Rahman
BHBrook K. Hemmelgarn
Brook K. Hemmelgarn
MWMichael A. Wyder
Michael A. Wyder
KKKarthickeyan Chella Krishnan
Karthickeyan Chella Krishnan
The role of peridroplet mitochondria (PDM) in diseased liver, such as during the progression of metabolic dysfunction-associated steatohepatitis (MASH), remains unknown. We isolated hepatic cytoplasmic mitochondria (CM) and PDM from a mouse model of diet-induced MASLD/MASH to characterize their functions from simple steatosis to advanced MASH, using chow-fed mice as controls. Our findings show an inverse relationship between hepatic CM and PDM levels from healthy to steatosis to advanced MASH. Proteomics analysis revealed these two mitochondrial populations are compositionally and functionally distinct. We found that hepatic PDM are more bioenergetically active than CM, with higher pyruvate oxidation capacity in both healthy and diseased liver. Higher respiration capacity of PDM was associated with elevated OXPHOS protein complexes and increased TCA cycle flux. In contrast, CM showed higher fatty acid oxidation capacity with MASH progression. Transmission electron microscopy revealed larger and elongated mitochondria during healthy and early steatosis, which appeared small and fragmented during MASH progression. These changes coincided with higher MFN2 protein levels in hepatic PDM and higher DRP1 protein levels in hepatic CM. These findings highlight the distinct roles of hepatic CM and PDM in MASLD progression towards MASH.

1 January 2026 in Case Reports in Pediatrics
Verified
Journal Article
Open access
NSNabil Saleem
Nabil Saleem
PSPamela B. Sylvestre
Pamela B. Sylvestre
FCFranklin L. Chien
Franklin L. Chien
RGRaul S. Gonzalez
Raul S. Gonzalez
JVJose E. Velázquez Vega
Jose E. Velázquez Vega
SMSarah Mitchell
Sarah Mitchell
Yolk sac tumors, a subset of malignant germ cell tumors originating from gonadal germ cells, most often present as ovarian or testicular tumors in adolescents, sometimes in combination with different types of histology as a mixed malignant germ cell tumor. We describe a female toddler presenting with severe iron deficiency anemia who was found to have a gastric pure yolk sac tumor. Pure yolk sac tumor of the stomach has rarely been reported and is even less frequent in the pediatric population. Our review of the medical literature found 12 case reports of gastric pure yolk sac tumor, of which only 1 was in a child, a 3‐year‐old male. Our patient underwent subtotal gastrectomy and received adjuvant systemic chemotherapy and is tumor‐free at 3 years following surgery. This is the first reported case of a gastric pure yolk sac tumor in a pediatric female, brought to clinical attention due to significant gastrointestinal blood loss.

26 December 2025 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
NANaim Alkhouri
Naim Alkhouri
PMParvez Mantry
Parvez Mantry
HGHumberto C. Gonzalez
Humberto C. Gonzalez
RPRashmee Patil
Rashmee Patil
VMVicki McIntyre
Vicki McIntyre
ASArun Sanyal
Arun Sanyal
Aim: This study evaluates the diagnostic performance of the novel blood-based device, LIVERFASt to detect fibrosis stages in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), including those with type 2 diabetes (T2DM), compared to FIB-4 in a subgroup analysis. Methods: LIVERFASt is computed with 10 blood biomarkers and four anthropometric measures and provides a quantitative score (0.00-1.00) to stage cirrhosis (F4), advanced fibrosis (≥F3), and clinically significant fibrosis (≥F2). Three cohorts of patients (two retrospective and one prospective) from tertiary centers in Europe and the U.S. with histological-proven biopsy were used to assess LIVERFASt and FIB-4 diagnostic performance using area under the receiver operating curve (AUROC), sensitivity (Sn), specificity, and predictive values (PV) for varying fibrosis prevalence levels. Results: 497 MASLD adult patients were included (median age 56 years, 56.7% female, 50.3% T2DM, 44.1% advanced fibrosis, and 20.1% cirrhosis). In the pooled analysis, the AUROCs for fibrosis stages F4, ≥F3, and ≥F2 were: 0.868, 0.846, 0.748, as well as for the T2DM subgroup (n=250): 0.846, 0.798, 0.736, respectively. For 35% advanced fibrosis prevalence, the positive/negative PVs were 77.2%/81.3% for the overall cohort and 65.52%/79.81% for the subgroup with tT2DM, respectively. At high (90%) to low (1%) advanced fibrosis prevalences, the positive and negative PVs ranged from 93% to 4.28% and from 43.06% to 99.73%, respectively. For F4 and ≥F3 fibrosis stages, LIVERFASt outperformed FIB-4: AUROC 0.870 vs 0.851 and 0.874 vs 0.821 (p<0.01), with Sn 74.07 vs 48.15 and 65.54 vs 37.29, respectively. Conclusions: LIVERFASt is a highly sensitive and clinically useful diagnostic test for staging fibrosis in MASLD patients, including those with T2DM and has a higher Sn for detecting advanced fibrosis when compared with FIB-4.